The Durham-based parent company says it still plans to grow Q2 Solutions’ local headcount despite the grant terminations.

Clinical research company IQVIA (NYSE: IQV) reported Q1 CY2025 results , with sales up 2.5% year on year to $3.83 billion. The company’s full-year revenue guidance of $16.2 billion at the ...

IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its fourth-quarter and full-year 2024 results and first-quarter and full-year 2025 guidance.

Webcast & Conference Call Details IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its fourth-quarter and full-year 2022 results and 2023 guidance.

IQVIA expects full-year earnings in the range of $11.70 to $12.10 per share, with revenue in the range of $16 billion to $16.4 billion. _____ This story was generated by Automated Insights ...

Looking ahead, IQVIA narrowed its full-year revenue guidance to a range of $15.43 billion to $15.53 billion from its prior forecast of $15.33 billion to $15.58 billion.

Full-year 2025 revenue guidance was raised by $275 million, now ranging between $16 billion and $16.4 billion, representing 3.9% to 6.5% reported growth. Adjusted EBITDA guidance remains at $3.765 ...

IQVIA to Announce First-Quarter 2025 Results on May 6, 2025. ... and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Clinical research company IQVIA (NYSE: IQV) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 2.5% year on year to $3.83 billion. The company’s full-year ...

RESEARCH TRIANGLE PARK, N.C., February 06, 2025--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to ...

Clinical research company IQVIA (NYSE: IQV) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 2.5% year on year to $3.83 billion. The company’s full-year revenue ...